RecruitingPhase 2

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

United States50 participantsStarted 2023-05-17

Plain-language summary

This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Absolute neutrophil count (ANC) \> 1.5 x 109/L
✓. Hemoglobin \> 9 g/dL
✓. Platelets (PLT) \> 70 x 109/L
✓. AST/ALT \< 5 x ULN
✓. Albumin within normal limits for institution

What they're measuring

Disease control rate (DCR):

Timeframe: From baseline until the date of first documented progression of disease, as assessed up to 100 months

Trial details

NCT IDNCT05806931

SponsorRutgers, The State University of New Jersey

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05-01

Contact for this trial

Howard S. Hochster, MD

732-253-5618 howard.hochster@rutgers.edu

View on ClinicalTrials.gov More Colon Cancer trials